Veru Inc. (NASDAQ:VERU – Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders purchased 9,142 call options on the company. This represents an increase of 206% compared to the average daily volume of 2,983 call options.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Veru in a research note on Thursday, January 2nd.
Veru Price Performance
Veru (NASDAQ:VERU – Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. As a group, sell-side analysts expect that Veru will post -0.22 earnings per share for the current year.
Insider Buying and Selling at Veru
In related news, Director Michael L. Rankowitz bought 95,279 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were bought at an average cost of $0.55 per share, for a total transaction of $52,403.45. Following the completion of the acquisition, the director now directly owns 195,279 shares in the company, valued at approximately $107,403.45. This represents a 95.28 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 14.90% of the company’s stock.
Institutional Investors Weigh In On Veru
Several hedge funds have recently modified their holdings of the business. PVG Asset Management Corp raised its stake in Veru by 64.4% during the 4th quarter. PVG Asset Management Corp now owns 1,047,310 shares of the company’s stock valued at $681,000 after purchasing an additional 410,340 shares during the last quarter. MPM Bioimpact LLC bought a new position in shares of Veru during the 4th quarter worth about $2,788,000. Cetera Investment Advisers raised its position in shares of Veru by 26.1% during the fourth quarter. Cetera Investment Advisers now owns 95,210 shares of the company’s stock valued at $62,000 after buying an additional 19,724 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Veru by 17.5% in the fourth quarter. Bank of America Corp DE now owns 217,792 shares of the company’s stock valued at $142,000 after buying an additional 32,447 shares during the period. Finally, Jane Street Group LLC grew its position in Veru by 35.2% during the fourth quarter. Jane Street Group LLC now owns 130,406 shares of the company’s stock worth $85,000 after buying an additional 33,952 shares in the last quarter. 47.16% of the stock is owned by institutional investors.
About Veru
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Featured Articles
- Five stocks we like better than Veru
- Why Are Stock Sectors Important to Successful Investing?
- Can TikTok Stock Picks Really Make You Rich?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- The “Quality” Rotation: Back to Basics Investing
- Dividend Payout Ratio Calculator
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.